Ernexa Therapeutics ERNAW Cash Flow Statement (2010-2026)

NASDAQ ERNAW
$0.06 +0.01 (+25.27%)
As of: Sep 4, 2026 · 3:55 PM EDT
Reported Financials

Ernexa Therapeutics Quarterly Cash Flow Statement

Periods 65 quarters
Latest Jun 2026

Ernexa Therapeutics reported cash from operations of -$4.12M and free cash flow of -$4.03M for the quarter ended Jun 2026, down 62.6% year over year. This cash flow statement covers 65 quarters of results from Jun 2010 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Jun2010 Sep2010 Dec2010 Mar2011 Jun2011 Sep2011 Dec2011 Mar2012 Jun2012 Sep2012 Dec2012 Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-85.99M-10.15M-9.38M-3.40M-7.32M-4.49M-5.42M-4.51M-5.59M-6.15M-6.65M-5.53M-26.60M-5.78M-8.20M-3.14M-1.24M-1.50M-5.51M-4.01M
Share-based Compensation
1.73M0.00M5.18M3.75M0.48M0.40M0.69M0.52M0.51M0.17M2.08M2.54M2.52M0.41M4.46M0.37M0.30M0.33M0.31M0.32M
Deferred Taxes
Cash from Discontinued Operations
Gains from Investment Securities
0.07M0.57M-1.02M-0.30M0.04M-0.19M-0.02M-0.05M0.07M-0.14M-0.83M0.48M-0.00M
Asset Writedowns and Impairment
5.99M0.01M
Cash from Restructuring
Non-cash Items
Cash from Operations
-6.42M-6.83M-5.43M-3.99M-6.12M-5.43M-6.05M-3.87M-5.83M-4.66M-3.75M-2.26M-6.29M-3.54M-2.06M-2.53M-1.30M-1.12M-2.30M-4.12M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles
0.09M0.10M0.10M0.08M0.08M0.07M0.04M0.04M0.50M0.46M0.50M0.53M0.41M0.05M0.05M0.04M0.05M0.06M0.08M0.04M
Amortization of Deferred Charges
0.10M0.25M0.45M0.50M1.23M3.11M
Depreciation & Amortization (CF)Depreciation & Amortization
0.03M0.02M0.04M0.07M0.04M0.02M0.02M0.02M0.02M0.02M0.04M0.04M0.04M0.02M0.02M0.02M0.02M0.01M0.01M0.01M
Change in Working Capital
Change in Receivables
0.66M
Change in Account Payables
3.39M-0.44M-0.44M-0.44M-0.44M-0.44M-0.44M-0.44M0.23M-0.56M-0.50M
Change in Accured Expenses
-1.66M-0.69M0.49M1.81M-0.92M0.66M-1.77M1.31M1.55M-4.00M0.46M1.09M-0.79M-0.57M-0.10M-0.36M0.30M0.22M0.76M-0.39M
Change in Taxes
Other Working Capital Changes
-0.40M-0.26M-0.30M1.02M-0.15M-0.92M-0.81M1.06M0.55M0.54M-0.81M1.80M-2.65M-0.05M-0.05M0.19M-0.28M0.41M0.32M0.06M
Investing Activities
Capital Expenditures
22.85M-0.07M0.30M0.10M0.32M0.11M0.37M2.43M-3.92M0.10M0.25M0.02M-0.00M0.02M0.01M0.00M-0.09M
Sales of Property, Plant and Equipment
0.10M0.20M0.00M
Divestments
Change in Acquisitions & Divestments
Cash from Investing Activities
-22.86M-0.15M-0.05M-0.09M-0.04M0.13M-0.02M-0.10M-0.25M-0.02M-0.01M-0.00M-0.00M
Financing Activities
Other financing activities
0.01M0.00M0.03M0.02M
Debt Issuance and Repayment
Long-Term Debt Issuances
16.50M1.41M2.48M2.25M
Long-Term Debt Repayments
Change in Capital Stock
Shares Issued
2.72M2.72M
Net Shares Issued and Repurchased
0.01M0.20M0.06M0.04M0.19M0.29M0.21M0.03M0.24M1.87M0.03M0.17M0.12M0.01M0.16M0.20M0.01M
Net Equity Issued and Repurchased
20.00M11.99M7.71M1.10M10.48M
Dividend Payments
Dividends Paid - Common
Misc.
Cash from Financing Activities
3.50M-0.42M11.99M-0.01M0.01M7.59M0.31M8.54M7.70M1.39M-0.02M3.89M1.01M2.25M4.93M0.03M9.56M0.01M
Exchange Rate Effect
Change in Cash
-25.78M-7.40M6.51M-4.09M-6.15M2.29M-6.05M-3.56M2.71M3.02M-2.46M-2.53M-2.42M-2.54M0.19M2.40M-1.27M-1.16M7.29M-4.15M
Free Cash Flow
-29.28M-6.83M-5.37M-4.29M-6.21M-5.75M-6.16M-4.25M-8.26M-0.74M-3.85M-2.51M-6.30M-3.54M-2.06M-2.53M-1.33M-1.13M-2.30M-4.03M
Net Cash Flow
-25.78M-7.40M6.51M-4.09M-6.15M2.29M-6.05M-3.56M2.71M3.02M-2.46M-2.53M-2.42M-2.54M0.19M2.40M-1.28M-1.13M7.26M-4.11M